C. Bell

发表

Cross-sectional survey study to examine underuse of twice daily inhaled maintenance therapy among patients with asthma

R. Stanford, C. Bell, A. Nag, 2019, The Journal of asthma : official journal of the Association for the Care of Asthma.

Clinical and economic outcomes associated with the use of fluticasone propionate 250 mcg and salmeterol 50 mcg combination versus tiotropium bromide 18 mcg as initial maintenance treatment for chronic obstructive pulmonary disease in managed care

C. Bell, A. Coutinho, E. Farrelly, 2018, Journal of medical economics.

Real-World Effectiveness of Belimumab in Systemic Lupus Erythematosus: A Systematic Literature Review

C. Bell, S. Snedecor, Shirley P Huang, 2022, Rheumatology and Therapy.

Cost Effectiveness of 5-Alpha Reductase Inhibitors for the Prevention of Prostate Cancer in Multiple Patient Populations

M. Kattan, L. Black, C. Bell, 2012, PharmacoEconomics.

PID3: TRENDS IN INPATIENT COSTS FOR ACUTE PANCREATITIS IN THE UNITED STATES

C. Pashos, J. Stephens, C. Bell, 2001 .

The Pursuit of Transparency and Quality Improvement in Cost-Effectiveness Analysis – A Case Study in Disease-Modifying Drugs for the Treatment of Multiple Sclerosis

C. Bell, 2011, Journal of managed care pharmacy : JMCP.

cross-sectional study The burden of Duchenne muscular dystrophy: An international,

C. Bell, E. Landfeldt, P. Lindgren, 2014 .

Clinical and epidemiologic burden of chronic myelogenous leukemia

C. Pashos, M. Botteman, B. Laskin, 2004, Expert review of anticancer therapy.

Muscular dystrophy-related hospitalizations among male pediatric patients in the United States

S. Kurosky, S. Candrilli, C. Bell, 2015, Hospital practice.

Prevalence of Eosinophilic Granulomatosis With Polyangiitis and Associated Health Care Utilization Among Patients With Concomitant Asthma in US Commercial Claims Database

M. Gokhale, J. Fairburn-Beech, M. V. Van Dyke, 2019, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

Observational vignette study to examine patient and healthcare provider perceived impact of asthma-related exacerbations in the US

L. Nelsen, C. Bell, Phaedra T. Johnson, 2019, Multidisciplinary Respiratory Medicine.

Real-World Effectiveness of Belimumab in Systemic Lupus Erythematosus: A Systematic Literature Review

C. Bell, S. Snedecor, Shirley P Huang, 2022, Rheumatology and Therapy.

Retrospective Analysis of Disease Severity, Health Care Resource Utilization, and Costs Among Patients Initiating Belimumab for the Treatment of Systemic Lupus Erythematosus.

C. Bell, A. Coutinho, T. Lokhandwala, 2021, Clinical therapeutics.

G.O.14 The burden of Duchenne muscular dystrophy: An international, cross-sectional study

K. Bushby, V. Straub, M. Guglieri, 2014, Neuromuscular Disorders.

Quantifying the burden of caregiving in Duchenne muscular dystrophy

Hanns Lochmüller, K. Bushby, V. Straub, 2016, Journal of Neurology.

Real-world Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the United States

M. C. Maher, C. Reyes, C. Bell, 2022, medRxiv.

A Randomized, Controlled Trial of Gabapentin Enacarbil in Subjects with Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

S. Schwartz, G. Meno-Tetang, R. Rauck, 2013, Pain practice : the official journal of World Institute of Pain.

Can Migraineurs Accurately Identify Their Headaches as “Migraine” at Attack Onset?

R. Cady, X. Hu, Ya-ting Chen, 2007, Headache.

Disease burden in patients with asthma before initiating biologics: A retrospective cohort database study.

H. Ortega, Salman Shams, C. Bell, 2019, Allergy and asthma proceedings.

The Direct Cost of Managing a Rare Disease: Assessing Medical and Pharmacy Costs Associated with Duchenne Muscular Dystrophy in the United States.

C. McDonald, C. Bell, S. Thayer, 2017, Journal of managed care & specialty pharmacy.

Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus

B. Yue, C. Bell, A. Coutinho, 2021, Lupus Science & Medicine.

Within- trialeconomicanalysisofflare data from the BLISS- SC trial of subcutaneous belimumab in systemic lupus erythematosus

B. Yue, C. Bell, A. Coutinho, 2021 .

Insights into the choice between intravenous infusion and subcutaneous injection: physician and patient characteristics driving treatment in SLE

C. Poulos, C. Bell, Melody Lee, 2020, Clinical Rheumatology.

Chronological characteristics of painful diabetic peripheral neuropathy: assessing the variation in daily pain intensity over the course of 7 days

M. Dibonaventura, B. Stacey, Susan A. Martin, 2010 .

Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study.

X. Hu, C. Bell, K. Foley, 2006, Clinical therapeutics.

Compliance to Care Guidelines for Duchenne Muscular Dystrophy

Hanns Lochmüller, K. Bushby, V. Straub, 2016, Journal of neuromuscular diseases.

A 5-Year Retrospective, Observational Study Assessing Rheumatoid Arthritis Disease Outcome Measures to Characterize Systemic Lupus Erythematosus Burden in the USA

D. Wallace, A. Concoff, M. Duh, 2022, Rheumatology and Therapy.

Effects of systemic corticosteroids on blood eosinophil counts in asthma: real-world data

H. Ortega, M. Duh, C. Bell, 2018, The Journal of asthma : official journal of the Association for the Care of Asthma.

Health care resource utilization and costs associated with nonfatal major adverse cardiovascular events.

Jennifer S. Korsnes, D. Mitra, K. Davis, 2015, Journal of managed care & specialty pharmacy.

Estimating preference-based EQ-5D health state utilities or item responses from neuropathic pain scores.

B. van Hout, M. Botteman, J. Carter, 2012, The patient.

Development and psychometric analysis of the Duchenne muscular dystrophy Functional Ability Self-Assessment Tool (DMDSAT)

A. Mayhew, H. Lochmüller, K. Bushby, 2015, Neuromuscular Disorders.

The burden of Duchenne muscular dystrophy

Hanns Lochmüller, K. Bushby, V. Straub, 2014, Neurology.

Hanns Lochmüller, K. Bushby, V. Straub, 2015, Developmental medicine and child neurology.

Health characteristics of patients with asthma, COPD and asthma–COPD overlap in the NHANES database

H. Ortega, M. Duh, C. Bell, 2018, International journal of chronic obstructive pulmonary disease.

Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA

A. Telenti, M. C. Maher, Daniel C Gibbons, 2023, Infectious Diseases and Therapy.

Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA

H. Kan, J. Priest, K. Costenbader, 2020, Lupus Science & Medicine.

Real-World Clinical Outcomes in Belimumab-Treated US African American and Hispanic Patients with Systemic Lupus Erythematosus: A Retrospective, Observational Study

C. Bell, B. Rubin, Jake Chung, 2023, Rheumatology and Therapy.

An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States

J. Meyers, C. Bell, Mayank Ajmera, 2022, Lupus.

Mapping of the Insomnia Severity Index and other sleep measures to EuroQol EQ-5D health state utilities

B. van Hout, M. Botteman, J. Carter, 2011, Health and quality of life outcomes.

The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States

C. Bell, Shirley P Huang, A. Cyhaniuk, 2022, Lupus.

Assessing the Impact of Migraine Onset on Work Productivity

S. Landy, C. Bell, Stephen H Landy, 2011, Journal of occupational and environmental medicine.

B. Goodwin, M. Eaddy, M. Runken, 2015, Applied Health Economics and Health Policy.

Value of cyclooxygenase-2 specific inhibitors in the management of osteoarthritis

C. Pashos, J. Stephens, C. Bell, 2004, Expert review of pharmacoeconomics & outcomes research.

Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States.

C. Pashos, A. Cohen, M. Botteman, 2002, Clinical therapeutics.

Impact of mepolizumab on exacerbations in severe asthma: Results from a U.S. insurance claims data base.

H. Ortega, C. Bell, B. Chastek, 2020, Allergy and asthma proceedings.

Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs

H. Ortega, E. Packnett, C. Bell, 2020, Journal of asthma and allergy.

Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype

Anand A. Dalal, S. Yancey, G. Canonica, 2017, Expert review of pharmacoeconomics & outcomes research.

Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States

C. Blauer-Peterson, C. Bell, Jianbin Mao, 2021, Journal of managed care & specialty pharmacy.

Evaluating the Use of Glucocorticoids Among Belimumab‐Treated Patients With Systemic Lupus Erythematosus in Real‐World Settings Using the Rheumatology Informatics System for Effectiveness Registry

J. Yazdany, G. Schmajuk, N. Hammam, 2022, ACR open rheumatology.

Within-trial economic analysis of resource use from COMET-ICE: A phase 3 clinical trial evaluating sotrovimab for the treatment of patients with COVID-19 at high risk of progression

H. Svedsater, C. Bell, E. Farrelly, 2022, Journal of managed care & specialty pharmacy.

Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States

Yongling Xiao, A. Swensen, M. Duh, 2016, Journal of managed care & specialty pharmacy.

Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.

J. Castelli-Haley, C. Bell, M. Oleen-Burkey, 2007, Journal of managed care pharmacy : JMCP.

Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study

M. Duh, C. Bell, J. Vu, 2023, ACR open rheumatology.

Prolonged oral corticosteroid treatment in patients with systemic lupus erythematosus: An evaluation of 12-month economic and clinical burden.

M. Duh, C. Bell, J. Vu, 2023, Journal of managed care & specialty pharmacy.

Burden of disease associated with a COPD eosinophilic phenotype

H. Ortega, M. Duh, C. Bell, 2018, International journal of chronic obstructive pulmonary disease.

Economic Model of First-Line Drug Strategies to Achieve Recommended Glycaemic Control in Newly Diagnosed Type 2 Diabetes Mellitus

J. Ramsdell, M. Botteman, S. Braunstein, 2012, PharmacoEconomics.

Cost-effectiveness of Four Immunomodulatory Therapies for Relapsing-Remitting Multiple Sclerosis: A Markov Model Based on Long-term Clinical Data

J. Castelli-Haley, C. Bell, M. Oleen-Burkey, 2007, Journal of managed care pharmacy : JMCP.

A randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of gabapentin enacarbil in subjects with neuropathic pain associated with postherpetic neuralgia (PXN110748).

R. Freeman, R. Harden, M. Rainka, 2013, The journal of pain : official journal of the American Pain Society.

health characteristics of patients with asthma, COPD and asthma–COPD overlap in the nhanes database

M. Duh, C. Bell, B. Hahn, 2018 .

Estimating Preference-Based EQ-5D Health State Utilities or Item Responses from Neuropathic Pain Scores

M. Botteman, J. Carter, C. Bell, 2012, The Patient - Patient-Centered Outcomes Research.

Clinical and Economic Burden of Systemic Lupus Erythematosus in the Years Preceding End-Stage Kidney Disease Diagnosis: A Retrospective Observational Study

C. Bell, Shirley P Huang, A. Guisinger, 2023, Rheumatology and Therapy.

Effects of systemic corticosteroids on blood eosinophil counts in asthma: real-world data

H. Ortega, M. Duh, C. Bell, 2018, The Journal of asthma : official journal of the Association for the Care of Asthma.